Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.538 estudios en Oncología (médica) (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The aims of this study are to evaluate the prevalence of vitamin D insufficiency among B/AA prostate cancer patients and to determine the deficits in immunity associated with vitamin D insufficiency. Also, we will evaluate whether the peripheral blood immune cell function is different in B/AA prostate cancer patients with metastatic disease as compared with those with localized disease. Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy Rochester, Minn. The purpose of this study is: To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review. To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection Mankato, Minn., La Crosse, Wis., Eau Claire, Wis., Albert Lea, Minn. The purpose of this study is to collect blood and tissue samples from patients with and without cancer to evaluate laboratory tests for early cancer detection which may help researchers develop tests for the early detection of cancers. A Study to Predict Response to Virotherapy and Immunotherapy by Using an Ex-Vivo Three-Dimensional Patient-Derived Organoid Model of Pediatric Urological Cancers Rochester, Minn. The purpose of this study is threefold: the first aim is to use patient-derived fresh tumor tissue to create cell lines and 3D tumor models (i.e. organoids) that preserve the characteristics of the original tumor. The preservation of the original tumor's drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy, immunotherapy) on these cell lines and 3D tumor models. The completion of the second aim is an important step towards developing a platform that can help guide treatment decisions for future patients, based on the drug response observed in the cell lines and 3D tumor models. The third aim is to use pan-omics approaches (i.e., genomics, proteomics, metabolomics) to find markers of drug response based on the results of the high-throughput drug testing on the cell lines and 3D tumor models. T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer Rochester, Minn. The purpose of this study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when administered to high risk patients with HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy. A Study to Evaluate Minimal Residual Disease in Chronic Lymphocytic Leukemia Rochester, Minn. The purpose of this study is to compare whether minimal residual disease (MRD) flow cytometric assay is not affected by different anticoagulants. A Study to Compare Somatostatin Analogues with Perioperative Antibiotics versus Prolonged Antibiotics Rochester, Minn. The purpose of this study is to to determine the individual treatment effect of somatostatin and whether duration of antibiotic therapy coupled with octreotide provides improved outcomes after pancreaticoduodenectomy. A Pilot Study to Evaluate the Molecular and Biological Phenotype of Peripheral Immune Cells in Solid Tumor Patients Rochester, Minn. The purpose of this study is to investigate for potential mechanisms underlying the sensitivity and resistance to immune checkpoint modulating agents that lead to the identification of sensitivity/resistance biomarkers and development of novel immunotherapeutic approaches. Advanced MR Imaging in Sarcoma Patients Rochester, Minn., Jacksonville, Fla. The purpose of this study is to compare the clinical application of two emerging magnetic resonance (MR) imaging modalities which Mayo Clinic has the technical capability of using, by adding them at the same time that standard imaging is done for patients receiving treatment for Ewing Sarcoma , Rhabdomyosarcoma and soft tissue sarcoma. A Study to Evaluate Regulation of the Metabolism of T-Cells by the Tumor Microenvironment in Ovarian Cancer Metastasis Scottsdale/Phoenix, Ariz. The purpose of this study is to analyze how the immune cell repertoire changes during early and late metastasis which could shed light into how the tumor microenvironment in metastatic disease becomes tumor permissive. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 1212 Ir a página 1313 Ir a página 1414 Ir a página 1515 Ir a página 1616 SiguientePróxima página Solicite una consulta Conocimientos y categoríasInvestigación May 09, 2023 Comparte en: FacebookTwitter Mayo Clinic en Rochester, Minnesota, Mayo Clinic en Jacksonville, Florida y Mayo Clinic en Phoenix y Scottsdale, Arizona, han sido reconocidas entre los mejores hospitales oncológicos en el país durante el período 2023-2024 por U.S. News and World Report. Lee más sobre este gran honor. Oncología (médica)Página inicialdel departamentoSeccionesDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicite una ConsultaDescripción generalEnfermedades tratadasMédicosGrupos especializadosConocimientos y categoríasEnsayos clínicosInvestigaciónExperiencias en Mayo Clinic y nuestros pacientes cuentan su historiaCostos y seguroNoticias de Mayo ClinicRemisiones ORG-20180179 Centros y departamentos médicos Oncología (médica)